Allergy最新文献

{"title":"Oral Immunotherapy in Peanut‐Allergic Adults Using Real‐World Materials","authors":"Hannah Hunter, Kok Loong Ue, Victoria Cornelius, Ching Ching Yung, Iason Thomas, Olympia Tsilochristou, Janice Layhadi, Leonard Q. C. Siew, Carina Venter, Mohamed H. Shamji, Stephen J. Till","doi":"10.1111/all.16493","DOIUrl":"https://doi.org/10.1111/all.16493","url":null,"abstract":"BackgroundPeanut oral immunotherapy (OIT) has shown effectiveness in achieving desensitization of children; however, evidence in adults is lacking.MethodsThis phase II trial evaluated peanut OIT in peanut‐allergic adults using real‐world peanut products. A Simon's minimax two‐stage design, incorporating a stop:go for futility, was employed. A separate untreated control group was also recruited for comparison of mechanistic parameters. Participants underwent baseline double‐blind placebo‐control food challenges (DBPCFC) with peanut protein doses of 0.3 to 300 mg. Reacting participants were initiated on daily OIT with 2‐weekly updosing until reaching a maintenance dose of 1000 mg (four large peanuts). The primary outcome was the proportion of OIT participants who tolerated a cumulative dose of 1.4 g peanut protein during exit DBPCFC (doses provided 0.3‐3000 mg).ResultsTwenty‐one adults (8 female; mean age 24.2 years [SD 4.9]) were enrolled in the OIT group, with 67% achieving the daily maintenance dose and meeting the primary endpoint. Three withdrew due to adverse reactions, and a further three did not complete the trial for reasons unrelated to OIT. The median tolerated dose increased from 30 mg (equivalent to approximately 1/8th of a peanut) to 3000 mg (12 peanuts) at the exit challenge, representing a 100‐fold increase (<jats:italic>p</jats:italic> &lt; 0.0001). OIT was associated with an improvement in QoL measures. Suppression of peanut skin prick test sizes and induction of peanut‐specific IgG were observed in OIT but not in control participants.ConclusionsPeanut OIT appears to be an efficacious treatment for adults with peanut allergy. Further studies are needed for confirmation and to characterize safety profiles in different adult subgroups.Trial RegistrationGrown Up Peanut Immunotherapy (GUPI) study; <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" xlink:href=\"http://clinicaltrials.gov\">ClinicalTrials.gov</jats:ext-link> identifier: NCT03648320","PeriodicalId":122,"journal":{"name":"Allergy","volume":"13 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143866843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fish Allergenicity Ladder and Parvalbumin Epitopes for Predicting Clinical Cross-Reactivity and Reintroduction in Chinese Population.","authors":"Christine Y Y Wai,Nicki Y H Leung,Agnes S Y Leung,Man Fung Tang,Åsa Marknell DeWitt,Jaime S Rosa Duque,Gilbert T Chua,Yat Sun Yau,Wai Hung Chan,Po Ki Ho,Mike Y W Kwan,Qun Ui Lee,Joshua S C Wong,Ivan C S Lam,James W C H Cheng,David C K Luk,Zhongyi Liu,Noelle Anne Ngai,Oi Man Chan,Patrick S C Leung,Gary W K Wong,Ting Fan Leung","doi":"10.1111/all.16562","DOIUrl":"https://doi.org/10.1111/all.16562","url":null,"abstract":"BACKGROUNDIgE-mediated fish allergy has long been considered an umbrella term due to the high cross-reactivity of parvalbumin, the major fish allergen. Yet, clinical tolerance to certain fish highlights allergenicity differences. In this study, we sought to construct a fish allergenicity ladder and identify fish parvalbumin epitopes to improve the diagnosis of fish allergy.METHODSReported clinical history and the serum-specific IgE (sIgE) responses of 200 Chinese subjects with suspected fish allergy were collected and analyzed, while the relative parvalbumin content in different fish was measured for the construction of a fish allergenicity ladder. Double-blind placebo-controlled food challenge (DBPCFC) and open challenge against salmon, grass carp, and grouper were performed in 58 selected patients for validation of the ladder. Epitope mapping was performed by peptide array against parvalbumins of salmon (both β-1 and β-2), cod, grouper, and grass carp with sera from fish allergic (n = 11), partial fish tolerant (n = 12), and complete fish tolerant (n = 5) patients diagnosed based on oral food challenge outcome.RESULTSThe distribution pattern of reported history of fish allergy and tolerance, sIgE and molecular data, as well as their strong positive correlation led to the construction of a 3-step fish allergenicity ladder comprising: step 1 of the least allergenic fishes (tuna, halibut, salmon and cod), steps 2 of moderately allergenic fishes (herring and grouper) to step 3 of highly allergenic fishes (catfish, grass carp and tilapia). Epitope mapping revealed one epitope from grouper parvalbumin (AA64-78) for diagnosing general fish allergy and one epitopic region from salmon parvalbumin (AA19-33) as a biomarker of specific fish tolerance. Only epitope-specific IgE differentiated these patients but not sIgE to fish extract or parvalbumin.CONCLUSIONThe fish ladder and epitopes discovery can precisely differentiate fish-allergic and tolerant subjects and guide fish reintroduction by stepping up the ladder, which innovates fish allergy care in the next millennium.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"7 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143871973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential DNA Methylation in Peripheral Blood Mononuclear Cells Reflects Asthma Control Status in Adults","authors":"Jin An, Jaehyun Park, Ah. Ra Do, Sujin Seo, Eunsoon Shin, Jong Eun Lee, You Sook Cho, Sungho Won, Tae‐Bum Kim","doi":"10.1111/all.16566","DOIUrl":"https://doi.org/10.1111/all.16566","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"28 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asthma Alleviation by Ginsenoside Rb1 via Promotion of Treg Proliferation and Inflammatory T Cell Inhibition","authors":"Susanna Choi, Seung‐Ah Yoo, Kon‐Young Ji, Dong Ho Jung, Saseong Lee, Kang‐Gu Lee, Ki‐Myo Kim, Joo Young Lee, Myung‐A Jung, Bo‐Jeong Pyun, Jung Hur, Joon Young Choi, Chin Kook Rhee, Wan‐Uk Kim, Taesoo Kim","doi":"10.1111/all.16551","DOIUrl":"https://doi.org/10.1111/all.16551","url":null,"abstract":"BackgroundRegulatory T cells (Tregs) are living drugs with feasibility, tolerability, and therapeutic benefits. Although Tregs are linked to asthma prognosis through inflammation regulation, no therapeutic agents specifically designed to manage asthma by upregulating Tregs have been developed to date.MethodsWe screened a library of 250 natural products using a cytometric bead array. Among the selected candidates, gRb1 was identified for further investigation. The effects of gRb1 on Treg and Th17 populations were evaluated in mouse asthma models and human PBMCs from both healthy donors and asthma patients using flow cytometry and cytokine analysis.ResultsIn inflammatory conditions, ginsenoside Rb1 (gRb1, a major ginseng component) increased IL‐10‐ and TGF‐β‐expressing Treg populations and decreased the Th17 population; activated phospho‐STAT5 and NFAT1 in Tregs; inhibited NFAT1 activation in conventional T cells (Tconvs); increased Treg proliferation and Tconv–Treg differentiation, inhibiting Tconv proliferation; and reduced inflammatory cytokine secretion by Tconvs. In asthma model mice, suppression of asthma symptoms by gRb1 was associated with elevated Treg and lower Th17, Th1, and Th2 counts. gRb1 treatment of stimulated PBMCs from patients with asthma and healthy donors increased IL‐10‐ and TGF‐β‐expressing Treg populations and decreased IL‐17A‐, IL‐22‐, IFN‐γ‐, and TNF‐α‐expressing T‐cell populations.ConclusionsgRb1 alleviate asthma by shifting the Treg–inflammatory T cell balance. These findings suggest a strategy for enhancing Treg activity through treatment with gRb1. This may provide a novel therapeutic approach for asthma and related disorders.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"56 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient‐Reported Outcomes in the Phase III OASIS‐HAE Study of Donidalorsen for Hereditary Angioedema","authors":"Marc A. Riedl, Aaron Yarlas, Laura Bordone, Sabrina Treadwell, Sophie Wang, Kenneth B. Newman, Danny M. Cohn","doi":"10.1111/all.16563","DOIUrl":"https://doi.org/10.1111/all.16563","url":null,"abstract":"BackgroundHereditary angioedema (HAE) is a rare disease characterized by unpredictable, frequently severe swelling that negatively impacts patients' quality of life (QoL). In the phase III OASIS‐HAE study (NCT05139810), donidalorsen reduced HAE attack rate, increased disease control, and improved QoL. Here, we report further analysis of donidalorsen's impact on QoL and other patient‐reported outcomes (PROs).MethodsThis double‐blind, placebo‐controlled study randomized patients with HAE to donidalorsen 80 mg or placebo once every 4 (Q4W) or 8 weeks (Q8W) over 24 weeks. PROs included Angioedema (AE)‐QoL Questionnaire, Angioedema Control Test (AECT), Patient Global Impression of Severity (PGIS), and Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions (WPAI+CIQ).ResultsNinety patients received donidalorsen Q4W (<jats:italic>n</jats:italic> = 45), donidalorsen Q8W (<jats:italic>n</jats:italic> = 23), or placebo (<jats:italic>n</jats:italic> = 22). A larger percentage of the donidalorsen Q4W group (88%) achieved clinically meaningful improvement (≥ 6‐point reduction) in AE‐QoL total score vs. placebo (45%). Both donidalorsen groups reported larger least‐squares mean (LSM) changes from baseline to week 24 vs. placebo in AE‐QoL functioning (difference: Q4W, −24.5; Q8W, −16.1), fears/shame (Q4W, −23.9; Q8W, −20.1), and nutrition (Q4W, −15.7; Q8W, −10.7) domains. Donidalorsen improved AECT scores vs. placebo (difference: Q4W, 6.0; Q8W, 4.1). A greater proportion of the donidalorsen Q4W group reported decreased disease severity vs. the placebo group (PGIS; 82% vs. 44%). Donidalorsen Q4W showed benefits vs. placebo in the presenteeism, overall work/school impairment, and activity impairment domains of the WPAI+CIQ.ConclusionsDonidalorsen significantly improved QoL and other PROs vs. placebo in patients with HAE.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"10 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Mast Cell Progenitors Are Depleted by Benralizumab in Severe Asthma.","authors":"Michael Fricker,John Harrington,Sarah A Hiles,Peter G Gibson","doi":"10.1111/all.16553","DOIUrl":"https://doi.org/10.1111/all.16553","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"25 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early‐Life Quarantine Increases the Development of Infant Atopic Dermatitis: A Birth Cohort Study in China","authors":"Yi Hu, Jiuru Zhao, Qianwen Shen, Dongjian Yang, Wei Li, Ze Chen, Meng Ni, Baihe Li, Zhenying Lin, Chunyu Cheng, Dongting Yao, Qianqian Zhang, Xiaorui Liu, Hong Li, Xiaoyi Huang, Zheng Tang, Zhiwei Liu","doi":"10.1111/all.16561","DOIUrl":"https://doi.org/10.1111/all.16561","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"32 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endothelin-1 Participates in the Pathogenesis of Prurigo Nodularis by Promoting NGF Expression via Endothelial Receptor B in Epidermal Keratinocytes and Dorsal Root Ganglion Cells.","authors":"Lai-San Wong,Jenq-Lin Yang,Yu-Ta Yen,Chih-Hung Lee,Jen-Hau Yang","doi":"10.1111/all.16564","DOIUrl":"https://doi.org/10.1111/all.16564","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"9 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143849474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Benefits of a Randomized Allergy App Intervention in Grass Pollen Sufferers: A Controlled Trial.","authors":"Caroline Holzmann,Johannes Karg,Matthias Reiger,Rajiv Kharbal,Paola Romano,Sabrina Scheiwein,Claudia Khalfi,Anna Muzalyova,Jens O Brunner,Gertrud Hammel,Athanasios Damialis,Claudia Traidl-Hoffmann,María P Plaza,Stefanie Gilles","doi":"10.1111/all.16558","DOIUrl":"https://doi.org/10.1111/all.16558","url":null,"abstract":"BACKGROUNDSymptom monitoring can improve adherence to daily medication. However, controlled clinical trials on multi-modular allergy apps and their various functions have been difficult to implement. The objective of this study was to assess the clinical benefit of an allergy app with varying numbers of functions in reducing symptoms and improving quality of (QoL) life in grass pollen allergic individuals. The secondary objective was to develop a symptom forecast based on patient-derived and environmental data.METHODSWe performed a stratified, controlled intervention study (May-August 2023) with grass pollen allergic participants (N = 167) in Augsburg, Germany. Participants were divided into three groups, each receiving the same allergy app, but with increasing numbers of functions.PRIMARY ENDPOINTrhinitis-related QoL; Secondary endpoints: symptom scores, relevant behavior, self-reported usefulness of the app, symptom forecast.RESULTSRhinitis-related QoL was increased after the intervention, with no statistical inter-group differences. However, participants with access to the full app version, including a pollen forecast, took more medication and reported lower symptoms and social activity impairment than participants with access to a reduced-function app. Using an XGBoost multiclass classification model, we achieved promising results for predicting nasal (accuracy: 0.79; F1-score: 0.78) and ocular (accuracy: 0.82; F1-score: 0.76) symptom levels and derived feature importance using SHAP as a guidance for future approaches.CONCLUSIONOur allergy app with its high-performance pollen forecast, symptom diary, and general allergy-related information provides a clinical benefit for allergy sufferers. Reliable symptom forecasts may be created given high-quality and high-resolution data.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"28 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Otitis Media With Effusion (OME) and Eustachian Tube Dysfunction: The Role of Allergy and Immunity-An EAACI Position Paper.","authors":"L Klimek,H A Brough,S Arasi,S Toppila-Salmi,C Bergmann,M Jutel,J Bousquet,V Hox,P Gevaert,P V Tomazic,C Rondón Segovia,C Cingi,M Cuevas,M Gröger,P Huber,S Reitsma,M Rudenko,J Maza-Solano,S Gane,A Karavelia,L van Gerven,M Schiappoli,B Bozkurt,S Becker,A Chaker,B Wollenberg,R Mösges,T Huppertz,J Hagemann,O Palomares,F Bärhold,O Pfaar,S Del Giacco,P Bonadonna,A Moreira,I Agache,C A Akdis,W Fokkens,J Walusiak-Skorupa,L de Las Vecillas,M Alvaro Lozano,M Giovannini,E Untersmayr,W Feleszko,A Cianferoni,U M Sahiner,I Eguiluz-Gracia,M Shamji,M J Torres Jaén","doi":"10.1111/all.16554","DOIUrl":"https://doi.org/10.1111/all.16554","url":null,"abstract":"IgE-mediated allergies play a significant role in respiratory diseases. Given the similar mucosal epithelium of the upper and lower respiratory tracts and their shared (patho)physiological immune responses, the \"unified airways\" concept views these tracts as a single system. Recently, this model has been extended to include the middle ear, with studies confirming that the Eustachian tube and middle ear are both anatomically and functionally part of the upper airways. However, the relationship between allergies and middle ear disorders remains controversial, with conflicting findings regarding pathogenesis and treatment. The increasing prevalence of allergies highlights the importance of further research. In Germany, the current sensitization rate to aeroallergens is 33.6%, with similar trends across Europe, where rates commonly range up to 30%. This widespread increase underscores the urgent need for a deeper understanding of the correlation between allergies and middle ear disorders across diverse European populations. Ineffective pharmacotherapy or possibly harmful medication for acute and chronic OME, such as systemic steroids, is most likely used globally in an uninformed way, due to a lack of evidence on the connection between allergic inflammation and eustachian tube dysfunction. Further research is essential to clarify the mechanisms linking IgE-mediated allergies to middle ear pathologies and to develop effective treatment strategies. Addressing these knowledge gaps is critical for improving patient outcomes and managing the rising burden of allergic diseases.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"7 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}